Free shipping on all orders $250CAD or more within Canada.

Tirzepatide

  • HOME
  • |
  • Tirzepatide

Tirzepatide

SKU TR202605B/TR402605D

Tirzepatide is a synthetic 39-amino-acid lipidated peptide designed as a dual agonist of the GIP and GLP-1 receptors. Researchers study it in laboratory and clinical settings for its effects on metabolic signalling, glucose regulation, appetite, lipid metabolism, energy balance and body-weight regulation.

Research involving Tirzepatide examines how simultaneous activation of GIP and GLP-1 receptor pathways may influence insulin signalling, nutrient metabolism, appetite-related signalling and changes in body composition. Its dual-receptor activity provides an important research model for studying the interaction between two major incretin pathways.

This material is intended for laboratory research only, is not authorized by Health Canada for human therapeutic use, and is not intended for human or veterinary administration.


CA$94.99

In Stock

Choose a kit option to save more, or skip this and buy individually above.

Save 5%
2 Vials x 20mg
CA$180.00 CA$190.00
Save 11%
4 Vials x 20mg
CA$320.00 CA$360.00
Save 19%
6 Vials x 20mg
CA$460.00 CA$570.00
Save 28%
10 Vials x 20mg
CA$680.00 CA$950.00
Save 9%
2 Vials x 40mg
CA$310.00 CA$340.00
Save 13%
4 Vials x 40mg
CA$590.00 CA$680.00
Save 20%
6 Vials x 40mg
CA$815.00 CA$1,020.00
Save 30%
10 Vials x 40mg
CA$1,190.00 CA$1,700.00
HPLC Purity Verified
Batch Documented
LC-MS Confirmation Available
2°C Storage

*LC-MS identity confirmation may be performed when analytical review indicates conflicting, atypical, or inconclusive results.

Tirzepatide Research Overview

What is Tirzepatide?

Tirzepatide is a synthetic, lipidated peptide engineered to interact with two important metabolic hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R).

Unlike compounds that selectively target only GLP-1 receptor signalling, Tirzepatide combines GIP and GLP-1 receptor activity within a single molecule. This dual-receptor design has made it an important research compound for investigating glucose homeostasis, insulin signalling, appetite regulation, nutrient metabolism, energy balance and body-weight regulation.

Structurally, Tirzepatide is a 39-amino-acid linear peptide derived primarily from the native GIP sequence and modified to provide activity at both GIP and GLP-1 receptors. A fatty-diacid side chain incorporated into the molecule promotes albumin association and contributes to its extended biological persistence.

Understanding Dual-Receptor Agonism

GIP and GLP-1 are naturally occurring incretin hormones released in response to nutrient intake. Both participate in the regulation of glucose-dependent insulin secretion, but each receptor also contributes additional metabolic signals.

GLP-1 receptor signalling is associated with glucose-dependent insulin secretion, glucagon regulation, gastric activity, appetite signalling and nutrient handling.

GIP receptor signalling is involved in glucose-responsive insulin signalling, nutrient metabolism and metabolic communication between pancreatic, adipose and other tissues.

Tirzepatide allows researchers to investigate the biological effects that occur when these two incretin pathways are activated simultaneously through a single molecular structure.

This combined activity provides a model for studying whether coordinated GIP and GLP-1 signalling produces metabolic responses that differ from selective activation of either receptor alone.

Glucose and Insulin Signalling Research

One of the primary areas of Tirzepatide research involves the regulation of glucose metabolism.

Both GIP and GLP-1 receptors participate in glucose-dependent pancreatic insulin signalling. Activation of these pathways is therefore studied for its effects on circulating glucose, insulin response, insulin sensitivity and broader metabolic homeostasis.

Researchers have investigated how dual-receptor activation may influence glucose handling under fasting and nutrient-stimulated conditions and how these effects interact with changes in body composition and energy balance.

Clinical and experimental research has demonstrated that Tirzepatide produces measurable changes in glycemic markers, making glucose regulation one of the most extensively studied aspects of its pharmacology.

Appetite and Body-Weight Research

Tirzepatide is also extensively studied in relation to appetite, food intake and body-weight regulation.

GLP-1 receptor signalling has an established role in pathways associated with satiety and food intake, while GIP receptor signalling may influence nutrient processing, adipose-tissue biology and metabolic responses to food.

Research involving simultaneous GIP and GLP-1 receptor activation has examined whether these pathways can interact to influence energy intake and longer-term changes in body composition.

Controlled human studies have demonstrated substantial changes in body weight within studied populations, creating considerable scientific interest in the mechanisms responsible for these observations. These findings apply to controlled clinical research and should not be interpreted as establishing equivalent outcomes for independently supplied research materials.

Lipid and Energy-Metabolism Research

Beyond glucose signalling, Tirzepatide research has examined changes in lipid metabolism, circulating triglycerides, waist circumference and several other cardiometabolic measurements.

These observations have encouraged broader investigation into how GIP and GLP-1 receptor signalling may influence substrate utilisation, adipose-tissue metabolism and overall energy balance.

The relationship between reduced energy intake, improved metabolic signalling and changes in adipose tissue remains an active area of scientific investigation.

Molecular Design

Tirzepatide is a 39-residue synthetic peptide based predominantly on the GIP peptide sequence.

Its molecular architecture incorporates several modifications designed to alter receptor activity, enzymatic stability and pharmacokinetic behaviour.

Important structural characteristics include:

  • 39 amino-acid residues
  • single linear peptide chain
  • GIP-derived peptide architecture
  • activity at both GIP and GLP-1 receptors
  • non-standard amino-acid substitutions
  • lipid modification attached through a lysine residue
  • hydrophilic linker structure
  • C20 fatty-diacid component
  • C-terminal amidation
  • albumin-binding characteristics

The lipid modification contributes to reversible albumin association and prolonged molecular persistence compared with an unmodified peptide sequence.

Receptor Pharmacology

Tirzepatide demonstrates activity at both GIPR and GLP-1R, although its pharmacological behaviour at the two receptors is not identical.

Experimental receptor studies indicate strong GIP receptor activity together with meaningful GLP-1 receptor agonism. This receptor profile distinguishes Tirzepatide from conventional selective GLP-1 receptor agonists.

Researchers continue to investigate how the relative balance between GIP and GLP-1 receptor activation contributes to metabolic outcomes observed in laboratory and clinical studies.

Human Research

Tirzepatide has been extensively evaluated in controlled human clinical research examining metabolic outcomes including glucose regulation, body weight, lipid measurements and other cardiometabolic parameters.

These studies provide significant information about the pharmacology of dual GIP/GLP-1 receptor activation and have expanded scientific interest in multi-receptor metabolic compounds.

Human clinical-trial findings apply specifically to the pharmaceutical material manufactured and administered under controlled clinical conditions. They do not establish identity, safety, sterility, potency or clinical equivalence for independently supplied research-grade material.

Important Evidence Limitations

Although Tirzepatide has a substantial human evidence base, published clinical research should be distinguished from laboratory research materials offered for analytical purposes.

Clinical studies use specifically manufactured material under defined protocols with established participant selection, dosing, monitoring and pharmaceutical quality controls.

Independently supplied laboratory material should therefore not be assumed to be equivalent to material used in published clinical studies.

HPLC purity also measures chromatographic purity and does not independently establish peptide identity, total peptide quantity, sterility, endotoxin content or suitability for biological administration.

These characteristics require separate analytical methods where applicable.

Research Status

Tirzepatide is extensively studied as a dual GIP/GLP-1 receptor agonist and has become an important reference compound in research investigating incretin biology, glucose metabolism, obesity, energy balance and multi-receptor metabolic signalling.

For laboratory research only. Not for human or veterinary use.

Tirzepatide Product Specifications

Product Identification

Product name: Tirzepatide

Compound type: Synthetic lipidated peptide

Research classification: Dual GIP / GLP-1 receptor agonist

Research category: Metabolic signalling and incretin-receptor research

CAS number: 2023788-19-2

Peptide length: 39 amino-acid residues

Available nominal strengths: 20 mg / 40 mg

Format: Lyophilized research material supplied in a sealed laboratory vial

Intended classification: Laboratory research reagent

Molecular Structure and Composition

Structural class: Single-chain lipidated synthetic peptide

Peptide backbone: GIP-derived peptide architecture

Molecular formula: C₂₂₅H₃₄₈N₄₈O₆₈

Molecular weight: Approximately 4,813 Da

Receptor targets: GIPR and GLP-1R

Lipid modification: C20 fatty-diacid moiety attached through a linker system

C-terminal structure: Amidated

Disulfide bonds: None

The molecular formula and molecular weight describe the defined modified Tirzepatide molecule and should be distinguished from alternative salt, counterion or analytical forms where applicable.

Physical Specifications

Physical form: Lyophilized powder

Typical appearance: White to off-white lyophilized material

Presentation: Sealed laboratory vial

Nominal vial content: As indicated on the individual product label and applicable batch documentation

Physical appearance alone does not establish peptide identity, purity or quantity.

Analytical Specifications

Primary purity assessment: High-performance liquid chromatography (HPLC)

Identity assessment: Mass-spectrometric or other identity analysis where specifically performed and reported

Purity specification: ≥99% where supported by the applicable batch Certificate of Analysis

Purity reporting: Batch-specific analytical value

Quantity/content determination: Reported independently where quantitative content testing has been performed

Acceptance reporting: Based on analytical documentation applicable to the individual production batch

HPLC purity represents the relative chromatographic purity of the analyzed sample and should not independently be interpreted as confirmation of total peptide quantity or vial content.

Batch-Testing Information

Each production batch should be identified using its individual lot or batch number and linked directly to its corresponding analytical documentation.

Where performed, batch documentation may include:

  • HPLC chromatographic purity analysis
  • mass-spectrometric identity assessment
  • quantitative content or mass determination
  • analytical laboratory information
  • batch or sample identification
  • date of testing
  • applicable Certificate of Analysis

Only analytical tests actually performed on the applicable batch should be represented as completed.

Sterility, endotoxin, microbial or pharmaceutical-quality attributes should not be implied unless specifically evaluated using an appropriate validated analytical method.

Storage Specifications

Recommended storage: 2–8°C

Light exposure: Protect from unnecessary light exposure

Moisture: Maintain material in a sealed, dry environment

Container: Keep vial securely closed until required for laboratory analysis

Stability: Batch-specific stability should not be assumed beyond available analytical or manufacturer documentation

Storage information relates solely to preservation of laboratory research material and does not constitute preparation or administration instructions.

Intended Use and Restrictions

Tirzepatide supplied under this specification is intended exclusively for:

  • laboratory research
  • analytical testing
  • GIP receptor research
  • GLP-1 receptor research
  • incretin-signalling studies
  • metabolic-pathway research
  • peptide-characterization studies
  • biochemical and molecular research
  • qualified scientific investigation

Not for human consumption.

Not for human or veterinary use.

Not intended for diagnosis, treatment, cure or prevention of disease.

Not represented as sterile or suitable for injection unless such characteristics have been independently established by appropriate validated testing.

Documentation Notice

Product specifications describe the general molecular identity and research classification of Tirzepatide.

Actual purity, quantity, identity and other analytical characteristics are batch-specific and should be determined from the Certificate of Analysis and associated laboratory documentation applicable to the individual lot.

Published scientific literature describing Tirzepatide under controlled experimental or clinical conditions should not be interpreted as analytical verification of independently supplied research material.

For laboratory research only. Not for human or veterinary use.

TESTING METHODOLOGY

Each batch undergoes analytical review using validated laboratory procedures. HPLC testing is utilized to assess purity and compare the sample profile against established reference standards. Where additional verification is warranted, LC-MS analysis may be performed to support compound identity confirmation.

OUR ANALYTICAL VERIFICATION PROGRAM

  • Primary Testing: HPLC purity analysis and reference comparison
  • Identity Confirmation: LC-MS performed when indicated*
  • Quality Standards: Batch traceability, analytical documentation, third-party testing and storage procedures

*See LC-MS Confirmation Information for full details.

Every batch supplied by Vanguard Compound Research is assigned a unique batch number and maintained under documented quality-control procedures with supporting analytical documentation available upon request.

SHIPPING & FULFILLMENT

FULFILLMENT INFORMATION
Ships from Canada

All orders ship from within Canada.

Batch Documentation Available

Batch records and analytical documentation may be provided for qualifying products.

Secure Packaging

Products are packaged securely to ensure safe delivery.

Tracking Provided

Tracking information is provided for every shipment.

Temperature-Conscious Handling

Frozen or ambient-safe packaging used as appropriate.

All Vanguard Compound Research orders are shipped directly from within Canada, ensuring efficient delivery, reliable service, and consistent quality-control from fulfillment to arrival.

Canadian Researchers Benefit From:

  • Domestic shipping with no customs delays
  • Batch-specific third-party laboratory testing
  • Full lot number traceability on every product
  • Access to batch-specific Certificates of Analysis (COAs)
  • Dedicated customer support

Canada-Wide Fulfillment:

  • Orders processed Monday through Friday
  • Shipments dispatched throughout Canada
  • Discreet and secure packaging
  • Tracking provided with every shipment

Batch Documentation & Testing

Products are maintained under documented quality-control procedures to help ensure quality, consistency, and transparency.

  • HPLC purity analysis
  • Reference-standard comparison
  • Additional verification procedures (e.g. LC-MS confirmation) may be performed where warranted
  • Lot number traceability

Each product is assigned a unique lot number, allowing researchers to match their item directly to its corresponding Certificate of Analysis (COA).

Analytical Documentation

Supporting analytical documentation may be available for qualifying products, including batch-specific quality records and testing information.

Documentation may include:
  • Batch Number
  • Analytical Results
  • Traceability Records
  • Storage Information

RELATED PRODUCTS